Jeffrey L. Cummings MD, ScD

Jeffrey L. Cummings

MD, ScD

Jeffrey L. Cummings, MD, ScD, is the Director of the Cleveland Clinic’s Lou Ruvo Center for Brain Health.

He is the Camille and Larry Ruvo Chair of the Neurological Institute of Cleveland Clinic and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Cummings is Principal Investigator/Director of the NIH/NIGMS-funded Center for Neurodegeneration and Translational Neuroscience.

Dr. Cummings is a world-renowned Alzheimer’s researcher and leader of clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through the Henderson Award of the American Geriatrics Society (2006), the Research Award of the John Douglas French Alzheimer’s Research Foundation (2008), and the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008). In 2010, he was honored by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award. In 2011, he was awarded a Doctor of Science by his Alma mater, University of Wyoming. He was featured in the Gentleman’s Quarterly (June 2009) as a “Rockstar of Science.”

Dr. Cummings is interested in clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society.

Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, Boston, Massachusetts. US training was followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London, England. Dr. Cummings was formerly Professor of Neurology and Psychiatry at UCLA, director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association.

Dr. Cummings has authored or edited 39 books and published over 650 peer-reviewed papers.

Employment History / Recent Positions

2012–present, The Camille and Larry Ruvo Chair for Brain Health

2010–present, Director
Cleveland Clinic Lou Ruvo Center for Brain Health

2010–2012, The Andrea L. and Joseph F. Hahn MD Chair of Neurotherapeutics
Cleveland Clinic, Neurological Institute

2009–2010, Director
Mary S. Easton Center for Alzheimer’s Disease Research at UCLA

2004–2010, Director
Deane F. Johnson Center for Neurotherapeutics at UCLA

2002–2008, Vice Chair
Department of Neurology, UCLA

1996–2010, Professor
The Augustus S. Rose Professor of Neurology at UCLA

1994–2010, Director
UCLA Dementia and Neurobehavior Research Fellowship

Education

University of Wyoming
1970 : Zoology/Philosophy : B.S.

University of Washington
1974 : Medicine : M.D.

University of Wyoming
2011 : Science : ScD.

Publications

  • Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer’s disease discovered in repurposed agents. Dement Geriatr Cogn Disord 2013; 35:1-22
  • Cummings JL, Banks SJ, Gary RK, Kinney JW, Lombardo JM, Walsh RR, Zhong K. Alzheimer’s disease drug development: translational neuroscience strategies. CNS Spectrums 2013;11:1-11
  • Pillai JA, Cummings JL. Clinical trials in predementia stages of Alzheimer disease. Med Clin North Am 2013;97:439-57.
  • Sabbagh JJ, Kinney JW, Cummings JL. Alzheimer’s disease biomarkers: Correspondence between human studies and animal models. Neurobiol Dis 2013;56:116-130.
  • Sabbagh JJ, Kinney JW, Cummings JL. Alzheimer’s disease biomarkers in animal models: closing the translational gap. Am J Neurodegener Dis 2013;21:108-20

Ongoing Research Support

  • COBRE (NIGMS) NIH-1 P20 GM109025-01A1 : 09/01/15-8/31/20
    This is a Center of BioMedical Research Excellence for support of a Center for Neurodgeneration and Translational Neuroscience (CNTN). It is comprised of cores—administrative, clinical, and data management—and 3 projects brain imaging in mild cognitive impairment in Parkinson’s disease, multimodal brain imaging assessment in Alzheimer’s disease, and behavioral assessment of a transgenic model of Alzheimer’s disease. The CNTN has essential components from the Cleveland Clinic Lou Ruvo Center for Brain Health and UNLV.
  • Rasagiline Rescue of Alzheimer’s Disease : 02/15/14-02/15/16
    PET to characterize the baseline and response to treatment with rasagiline in a double blind, randomized, placebo controlled, parallel group. The trial capitalizes on the Cleveland Clinic trial network with 2 sites in Cleveland 1 in
    Las Vegas.